KR20210076222A - Calcium absorption promoting composition comprising cocoon hydrolysate - Google Patents
Calcium absorption promoting composition comprising cocoon hydrolysate Download PDFInfo
- Publication number
- KR20210076222A KR20210076222A KR1020190166223A KR20190166223A KR20210076222A KR 20210076222 A KR20210076222 A KR 20210076222A KR 1020190166223 A KR1020190166223 A KR 1020190166223A KR 20190166223 A KR20190166223 A KR 20190166223A KR 20210076222 A KR20210076222 A KR 20210076222A
- Authority
- KR
- South Korea
- Prior art keywords
- cocoon
- hydrolyzate
- present
- food composition
- calcium
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 239000011575 calcium Substances 0.000 title claims abstract description 45
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 45
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 29
- 230000001737 promoting effect Effects 0.000 title claims abstract description 19
- 239000000413 hydrolysate Substances 0.000 title abstract 3
- 235000013305 food Nutrition 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 25
- 230000036541 health Effects 0.000 claims abstract description 18
- 150000001413 amino acids Chemical class 0.000 claims abstract description 11
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- 235000019658 bitter taste Nutrition 0.000 claims abstract description 7
- 235000019614 sour taste Nutrition 0.000 claims abstract description 6
- 108010013296 Sericins Proteins 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 235000000346 sugar Nutrition 0.000 claims description 12
- 229940024606 amino acid Drugs 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 206010006956 Calcium deficiency Diseases 0.000 claims description 9
- 238000010306 acid treatment Methods 0.000 claims description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
- 230000001953 sensory effect Effects 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims description 4
- 238000011033 desalting Methods 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 206010043376 Tetanus Diseases 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 208000007442 rickets Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 208000005368 osteomalacia Diseases 0.000 claims description 2
- 238000007670 refining Methods 0.000 claims 1
- 241000255789 Bombyx mori Species 0.000 abstract description 7
- 239000000654 additive Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 108010009736 Protein Hydrolysates Proteins 0.000 abstract 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 108010022355 Fibroins Proteins 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000003674 animal food additive Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- -1 pH adjusters Substances 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 235000019583 umami taste Nutrition 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000009991 scouring Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 230000037152 sensory function Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000019607 umami taste sensations Nutrition 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000019779 Rapeseed Meal Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000004456 rapeseed meal Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L35/00—Food or foodstuffs not provided for in groups A23L5/00 – A23L33/00; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/16—Taste affecting agent
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Insects & Arthropods (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 누에고치 가수분해물에 관한 것으로, 보다 상세하게는, 상기 누에고치 가수분해물을 포함하는 조성물 및 이의 제조방법에 관한 것이다.The present invention relates to a cocoon hydrolyzate, and more particularly, to a composition comprising the cocoon hydrolyzate and a method for preparing the same.
칼슘은 인체에 가장 많이 존재하는 무기질 원소로 일반 성인의 경우 체중의 약 2%인 1,200 g 정도를 체내에 보유하고 있다. 체내의 칼슘 중 99%는 골격 및 치아를 형성하고 있으며, 나머지 1%는 근육의 수축과 이완, 규칙적 심장박동 혈액응고, 효소의 활성화, 세포 내 자극 및 흥분의 전달과 같은 생리활성 조절 기능을 담당한다. 혈청 내 칼슘의 농도는 항상 일정하게 유지된다. 하지만 칼슘의 공급이 장기간 결핍되면 골격 및 치아로부터 빠져나와 골다공증, 구루병, 테타니 등의 결핍증이 유발되며, 이에 따라 칼슘 농도가 낮아진 뼈는 골절되기 쉽다. Calcium is the most abundant mineral element in the human body, and in the case of an average adult, about 1,200 g, about 2% of the body weight, is contained in the body. 99% of the calcium in the body forms the skeleton and teeth, and the remaining 1% is responsible for regulating physiological activities such as muscle contraction and relaxation, regular heartbeat blood coagulation, activation of enzymes, and transmission of intracellular stimulation and excitement. do. The concentration of calcium in the serum is always kept constant. However, if the supply of calcium is deficient for a long time, it escapes from the skeleton and teeth, and deficiency such as osteoporosis, rickets, and tetanus is induced.
한편, 음식으로부터 섭취된 칼슘은 장에서 흡수되나, 그 흡수율이 비교적 낮으며, 칼슘의 존재 형태, 섭취량 및 비타민 등의 요소에 의해 큰 영향을 받는다. 최근 체내 칼슘의 중요성이 대두됨으로써, 칼슘의 체내 이용률을 높이기 위한 연구가 활발히 진행되고 있다. 일반적으로 칼슘 이온은 인산 이온과 공존하면 인산칼슘을 형성하여 침전된다. 생체 내 칼슘은 소장에서 과량의 인산이온에 의해 침전되어 체내로 흡수되지 않고 배설된다. 대표적인 칼슘 흡수 촉진제로는, 카제인의 세린 잔기에 인산기가 결합되어 있는 형태인 카세인 인산펩타이드(casein phosphopeptide, CPP)가 가장 대표적이나, 이는 식품 등에 첨가할 경우 기호도가 감소한다는 한계가 있다.On the other hand, calcium ingested from food is absorbed in the intestine, but its absorption rate is relatively low, and it is greatly affected by factors such as the presence form of calcium, intake amount and vitamins. Recently, as the importance of calcium in the body has emerged, research to increase the utilization rate of calcium in the body is being actively conducted. In general, when calcium ions coexist with phosphate ions, they form calcium phosphate and precipitate. Calcium in the living body is precipitated by excess phosphate ions in the small intestine and is excreted without being absorbed into the body. As a representative calcium absorption enhancer, casein phosphopeptide (CPP), which is a form in which a phosphate group is bonded to a serine residue of casein, is the most representative, but this has a limitation in that the preference decreases when added to food.
이에 본 발명자들은 기호도를 감소시키지 않는 칼슘 흡수 촉진제를 개발하기 위하여 연구하던 중, 누에고치 가수분해물의 칼슘 흡수 촉진 및 기호도 증가 효과를 확인함으로써 본 발명을 완성하게 되었다.Accordingly, the present inventors completed the present invention by confirming the effect of promoting calcium absorption and increasing the preference of the cocoon hydrolyzate while researching to develop a calcium absorption enhancer that does not reduce the preference.
따라서 본 발명의 목적은, 누에고치 가수분해물을 포함하는 칼슘 흡수 촉진용 조성물을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a composition for promoting calcium absorption comprising a cocoon hydrolyzate.
본 발명의 다른 목적은, 누에고치 가수분해물을 포함하는 칼슘 결핍으로 인한 질환의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for preventing or treating diseases caused by calcium deficiency, including a hydrolyzate of cocoon.
본 발명의 또 다른 목적은, 상기 칼슘 흡수 촉진 및 관능이 개선된 식품 조성물의 제조방법을 제공하는 것이다.Another object of the present invention is to provide a method for preparing a food composition having improved calcium absorption and sensory function.
상기 목적을 달성하기 위하여, 본 발명은 누에고치 가수분해물을 포함하는 칼슘 흡수 촉진용 식품 조성물을 제공한다.In order to achieve the above object, the present invention provides a food composition for promoting calcium absorption comprising a cocoon hydrolyzate.
또한, 본 발명은 누에고치 가수분해물을 포함하는, 성장기 칼슘 흡수 촉진용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for promoting calcium absorption in the growth phase, comprising a cocoon hydrolyzate.
또한, 본 발명은 누에고치 가수분해물을 포함하는 칼슘 흡수 촉진용 사료 조성물을 제공한다.In addition, the present invention provides a feed composition for promoting calcium absorption comprising a cocoon hydrolyzate.
또한, 본 발명은 누에고치 가수분해물을 포함하는 칼슘 결핍으로 인한 질환의 예방 또는 치료용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating a disease caused by calcium deficiency comprising a hydrolyzate of a cocoon.
또한, 본 발명은 누에고치의 세리신을 제거하는 단계; 세리신이 제거된 누에고치를 산 처리하여 용해시키는 단계; 및 용해물을 중화 및 탈염하는 단계;를 포함하는 칼슘 흡수 촉진 및 관능이 개선된 식품 조성물 제조방법을 제공한다.In addition, the present invention comprises the steps of removing the sericin of the cocoon; Dissolving the cocoon from which sericin has been removed by acid treatment; and neutralizing and desalting the lysate; provides a method for preparing a food composition having improved calcium absorption and sensory function.
본 발명에 따른 누에고치 가수분해물은 단맛을 나타내는 특정 아미노산의 함량이 증진되었을 뿐 아니라 체내 칼슘 흡수 촉진 효과가 우수하다. 또한 상기 누에고치 가수분해물은 단맛이 증가하고, 쓴맛 및 신맛이 감소하여 종합적인 기호도가 현저히 증가하였다. 따라서 본 발명의 누에고치 가수분해물은 첨가제, 건강기능식품, 사료 등을 포함하는 식품 분야에서 다양하게 활용될 수 있다.The hydrolyzate of the cocoon according to the present invention not only has an enhanced content of a specific amino acid exhibiting sweetness, but also has an excellent effect of promoting calcium absorption in the body. In addition, the hydrolyzate of the cocoon increased the sweetness, and the bitterness and sour taste were decreased, so that the overall preference was significantly increased. Therefore, the cocoon hydrolyzate of the present invention can be variously used in the food field including additives, health functional foods, feeds, and the like.
도 1은 본 발명에 따른 정련견을 이용한 누에고치 가수분해물 제조방법을 나타낸 도이다.
도 2는 실험동물에서 본 발명에 따른 누에고치 가수분해물의 칼슘 흡수 촉진 효과를 나타낸 도이다.1 is a view showing a method for producing a cocoon hydrolyzate using a refined dog according to the present invention.
2 is a diagram showing the effect of promoting calcium absorption of a cocoon hydrolyzate according to the present invention in an experimental animal.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 양태에 따르면, 본 발명은 누에고치 가수분해물을 포함하는 칼슘 흡수 촉진용 식품 조성물 또는 성장기 칼슘 흡수 촉진용 건강기능식품 조성물을 제공한다.According to an aspect of the present invention, the present invention provides a food composition for promoting calcium absorption or a health functional food composition for promoting calcium absorption during growth, comprising a hydrolyzate of cocoon.
본 발명의 구체예에서, 상기 누에고치는 세리신이 제거된 누에고치, 즉, 정련견인 바람직하다.In an embodiment of the present invention, the cocoon is a cocoon from which sericin has been removed, that is, it is preferably a scouring dog.
본 발명의 구체예에서, 상기 가수분해물은 상기 누에고치 가수분해물은 아스파르트산, 이소루신, 타이로신 페닐알라닌 및 프롤린으로 이루어진 군에서 선택된 1 이상의 아미노산 함량이 세리신 및 피브로인보다 증진된 것이 바람직하나, 이에 제한되지 않는다.In an embodiment of the present invention, the hydrolyzate of the cocoon hydrolyzate has at least one amino acid selected from the group consisting of aspartic acid, isoleucine, tyrosine phenylalanine and proline. does not
본 발명의 구체예에서, 상기 누에고치 가수분해물은 당도가 증진된 것이 바람직하다. 보다 구체적으로 누에고치 가수분해물의 당도는 5 내지 16 brix일 수 있으며, 10 내지 12 brix인 것이 더 바람직하나, 이에 제한되지 않는다.In an embodiment of the present invention, it is preferable that the hydrolyzate of the cocoon has improved sugar content. More specifically, the sugar content of the cocoon hydrolyzate may be 5 to 16 brix, more preferably 10 to 12 brix, but is not limited thereto.
본 발명의 구체예에서, 상기 누에고치 가수분해물은 쓴맛 및 신맛이 감소된 것이 바람직하다.In an embodiment of the present invention, it is preferable that the hydrolyzate of the cocoon has reduced bitterness and sour taste.
본 발명에 따른 누에고치 가수분해물은 유리 아미노산 함량 증가 및 체내 칼슘 흡수 촉진 효과가 우수한 것을 확인하였다. 뿐만 아니라 상기 누에고치 가수분해물은 쓴맛 및 신맛은 감소하고, 당도(즉, 단맛)가 증가하여 종합적인 기호도가 현저히 높은 것을 확인하였다. It was confirmed that the hydrolyzate of cocoon according to the present invention was excellent in increasing the free amino acid content and promoting calcium absorption in the body. In addition, it was confirmed that the hydrolyzate of the cocoon decreased bitter and sour taste, and increased sugar content (ie, sweetness), resulting in significantly higher overall preference.
본 발명의 누에고치 가수분해물은 건강기능식품, 식품 첨가제 또는 식이보조제로 사용될 수 있다. 상기 누에고치 가수분해물이 식품 첨가제로 사용할 경우, 상기 누에고치 가수분해물을 그대로 첨가하거나, 다른 식품 또는 식품 성분과 함께 혼합하여 사용되는 등 통상적인 방법에 따라 적절하게 사용될 수 있다.The cocoon hydrolyzate of the present invention may be used as a health functional food, a food additive, or a dietary supplement. When the hydrolyzate of the cocoon is used as a food additive, the hydrolyzate of the cocoon may be added as it is or may be appropriately used according to a conventional method such as mixing with other foods or food ingredients.
구체적인 예로, 식품 또는 음료의 제조 시에는 본 발명의 누에고치 가수분해물은 원료에 대하여 15중량% 이하, 바람직하게는 10중량% 이하의 양으로 첨가된다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하여 장기간 섭취할 경우에는 상기 범위 이하의 양으로 첨가될 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다. 상기 식품의 종류에는 특별한 제한은 없으나, 본 발명의 누에고치 가수분해물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 수프, 음료수, 차, 드링크제, 알코올 음료, 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.As a specific example, in the production of food or beverage, the cocoon hydrolyzate of the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less, based on the raw material. However, when consumed for a long period of time for health and hygiene or health control, it may be added in an amount less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range. have. There is no particular limitation on the type of the food, but examples of the food to which the cocoon hydrolyzate of the present invention can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, and ice cream. There are dairy products including dairy products, various soups, beverages, teas, drinks, alcoholic beverages, vitamin complexes, etc., and includes all health foods in a normal sense.
본 발명의 식품 조성물이 음료로 제조될 경우 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등의 추가 성분을 포함할 수 있다. 상기 천연 탄수화물로는 포도당, 과당 등의 모노사카라이드; 말토오스, 수크로오스 등의 디사카라이드; 덱스트린, 사이클로덱스트린 등의 천연 감미제; 사카린, 아스파르탐 등의 합성 감미제 등이 사용될 수 있다. 상기 천연 탄수화물은 본 발명의 식품 조성물 총 중량에 대하여 0.01 내지 10중량%, 바람직하게는 0.01 내지 0.1중량%로 포함된다.When the food composition of the present invention is prepared as a beverage, it may contain additional ingredients such as various flavoring agents or natural carbohydrates like conventional beverages. Examples of the natural carbohydrate include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; natural sweeteners such as dextrin and cyclodextrin; Synthetic sweeteners such as saccharin and aspartame may be used. The natural carbohydrate is included in an amount of 0.01 to 10% by weight, preferably 0.01 to 0.1% by weight, based on the total weight of the food composition of the present invention.
본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 포함할 수 있으며, 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 포함할 수 있으나 이에 제한되지 않는다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 상기의 첨가제 비율은 크게 제한되지는 않으나, 본 발명의 식품 조성물 총 중량에 대하여 0.01 내지 0.1중량% 범위내로 포함되는 것이 바람직하다.The food composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonic acid It may include a carbonation agent used in beverages, and the like, and may include, but is not limited to, the flesh for the production of natural fruit juice, fruit juice beverage, and vegetable beverage. These components may be used independently or in combination. Although the additive ratio is not particularly limited, it is preferably included in the range of 0.01 to 0.1% by weight based on the total weight of the food composition of the present invention.
건강 및 위생을 목적으로 하거나 건강 조절을 목적으로 하는 장기간의 섭취인 경우, 본 발명의 식품 조성물은 안전성 면에서 아무런 문제가 없기 때문에 장기간 복용이 가능하다.In the case of long-term ingestion for health and hygiene purposes or for health control, the food composition of the present invention can be taken for a long time because there is no problem in terms of safety.
본 발명의 또 다른 양태에 따르면, 본 발명은 누에고치 가수분해물을 포함하는 칼슘 흡수 촉진용 사료 조성물을 제공한다.According to another aspect of the present invention, the present invention provides a feed composition for promoting calcium absorption comprising a cocoon hydrolyzate.
본 발명의 사료 조성물은 사료첨가제 또는 배합사료일 수 있다.The feed composition of the present invention may be a feed additive or a compound feed.
본 발명에 있어서, “사료첨가제”는 영양적 또는 특정 목적을 위하여 사료에 미량으로 첨가되는 물질을 의미하는 것으로서, 본 발명의 기능성 사료첨가제는 누에고치 가수분해물 그 자체이거나 공지의 사료 첨가물들과 일정 비율로 배합될 수 있다. 배합되는 경우 누에고치 가수분해물은 사료첨가제 전체 중량에서 0.01 내지 99 중량%가 적용될 수 있다.In the present invention, "feed additive" refers to a substance added to the feed in a trace amount for nutritional or specific purposes, and the functional feed additive of the present invention is either a cocoon hydrolyzate itself or a certain amount of known feed additives. can be combined in proportions. When formulated, the cocoon hydrolyzate may be applied in an amount of 0.01 to 99% by weight based on the total weight of the feed additive.
본 발명의 사료 조성물은 배합사료 100중량부에 대하여 누에고치 가수분해물을 유효성분으로 함유하는 사료첨가제 0.1 내지 5중량부를 포함한다. 배합사료의 일 예로 옥수수 53.71중량%, 대두박 23.2중량%, 채종박 1.0중량%, 옥배아박 2.0중량%, 주정박 3.0중량%, 소맥피 2.7중량%, 감자전분 0.3중량%, 유지 2.8중량%, 탄산칼슘 9.9중량%, 제2인산칼슘 0.68중량%, 염화나트륨 0.23중량%, 인 분해효소제 0.03중량%, 염화콜린 0.05중량%, 메치오닌 0.2중량%, 미네랄 믹스 0.1중량%, 비타민 믹스 0.1중량%로 조성된다. 이외에도 통상적인 양계용 배합사료가 이용될 수 있음은 물론이다. 또한, 배합사료는 사육대상인 가축의 종류에 따라 소, 돼지, 오리 등의 배합사료가 이용될 수 있음은 물론이다.The feed composition of the present invention contains 0.1 to 5 parts by weight of a feed additive containing a cocoon hydrolyzate as an active ingredient with respect to 100 parts by weight of the compounded feed. As an example of a compound feed, 53.71 wt% of corn, 23.2 wt% of soybean meal, 1.0 wt% of rapeseed meal, 2.0 wt% of jade germ meal, 3.0 wt% of distilled gourd, 2.7 wt% of wheat blood, 0.3 wt% of potato starch, 2.8 wt% of oil , calcium carbonate 9.9% by weight, dibasic calcium phosphate 0.68% by weight, sodium chloride 0.23% by weight, phosphatase 0.03% by weight, choline chloride 0.05% by weight, methionine 0.2% by weight, mineral mix 0.1% by weight, vitamin mix 0.1% by weight is made up In addition, of course, a conventional compound feed for poultry may be used. In addition, as for the compounded feed, of course, a compounded feed such as cattle, pigs, and ducks may be used depending on the type of livestock to be reared.
상기 사료 조성물을 급이하여 가축을 사육할 수 있으며, 가축의 사육 시 누에고치 가수분해물을 물에 희석하여 식수로 제공될 수 있다.Livestock may be raised by feeding the feed composition, and the cocoon hydrolyzate may be diluted in water to provide drinking water during breeding of livestock.
본 발명의 사료 조성물은 당업자가 예상할 수 있는 범위 내의 다른 기타 영양성분을 추가로 포함할 수 있다.The feed composition of the present invention may further include other nutrients within the range that those skilled in the art would expect.
본 발명의 누에고치 가수분해물은 상업적으로 통상적인 동물 사료 조성물 내로 혼입될 수 있고, 예를 들어, 소, 돼지, 양, 가금류 등에 공급될 수 있다. 이를 위해 본 발명의 누에고치 가수분해물은 통상적인 동물 사료 구성 성분들과 혼합될 수 있고, 필요하다면 정제된 형태로 가공될 수 있다. 통상적인 동물 사료 구성 성분은 예를 들어, 옥수수, 보리, 귀리, 대두, 어분, 겨, 대두유, 무기물, 미량 원소, 아미노산 및 비타민이다.The cocoon hydrolyzate of the present invention can be incorporated into commercially customary animal feed compositions and fed, for example, to cattle, pigs, sheep, poultry, and the like. For this purpose, the cocoon hydrolyzate of the present invention may be mixed with conventional animal feed ingredients and, if necessary, processed into a purified form. Typical animal feed ingredients are, for example, corn, barley, oats, soybeans, fish meal, bran, soybean oil, minerals, trace elements, amino acids and vitamins.
본 발명의 또 다른 양태에 따르면, 본 발명은 누에고치 가수분해물을 포함하는 칼슘 결핍으로 인한 질환의 예방 또는 치료용 약학적 조성물을 제공한다.According to another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating a disease caused by calcium deficiency, comprising a cocoon hydrolyzate.
본 발명의 약학적 조성물은 통상의 방법에 따라 다양한 형태로 제형화하여 사용될 수 있다. 예컨대, 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽 등의 경구형 제형으로 제형화할 수 있고, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition of the present invention may be formulated and used in various forms according to conventional methods. For example, it may be formulated in oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, etc., and may be formulated in the form of external preparations, suppositories, and sterile injection solutions.
본 발명의 조성물은 누에고치 가수분해물과 함께 칼슘 결핍으로 인한 질환에 대하여 예방 또는 치료 효과를 갖는 공지의 유효성분을 1종 이상 함유할 수 있다.The composition of the present invention may contain one or more known active ingredients having a preventive or therapeutic effect on a disease caused by calcium deficiency together with a cocoon hydrolyzate.
본 발명의 구체예에서, 상기 칼슘 결핍으로 인한 질환은 구루병, 골다공증, 골연화증, 테타니, 부종, 고콜레스테롤증, 동맥경화, 고지혈증 및 고혈압으로 이루어진 군에서 선택된 1 이상인 것이 바람직하며, 칼슘 결핍으로 인해 발병되는 질환이라면 이에 제한되지 않는다.In an embodiment of the present invention, the disease caused by calcium deficiency is preferably at least one selected from the group consisting of rickets, osteoporosis, osteomalacia, tetanus, edema, hypercholesterolemia, arteriosclerosis, hyperlipidemia and hypertension, and is caused by calcium deficiency The disease is not limited thereto.
본 발명의 조성물은 약제학적으로 허용 가능한 첨가제를 더 포함할 수 있으며, 이때 약제학적으로 허용 가능한 첨가제로는 전분, 젤라틴화 전분, 미결정셀룰로오스, 유당, 포비돈, 콜로이달실리콘디옥사이드, 인산수소칼슘, 락토스, 만니톨, 엿, 아라비아고무, 전호화전분, 옥수수전분, 분말셀룰로오스, 히드록시프로필셀룰로오스, 오파드라이, 전분글리콜산나트륨, 카르나우바납, 합성규산알루미늄, 스테아린산, 스테아린산마그네슘, 스테아린산알루미늄, 스테아린산칼슘, 백당 등이 사용될 수 있다. 본 발명에 따른 약제학적으로 허용 가능한 첨가제는 상기 조성물에 대해 0.1 ~ 90 중량부 포함되는 것이 바람직하나 이에 한정되는 것은 아니다.The composition of the present invention may further include a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additive includes starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, and lactose. , mannitol, syrup, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, Sucrose and the like may be used. The pharmaceutically acceptable additive according to the present invention is preferably included in an amount of 0.1 to 90 parts by weight based on the composition, but is not limited thereto.
본 발명의 조성물은 실제 임상투여 시에 경구 또는 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제할 수 있으며, 당해 기술 분야에 알려진 적합한 제제는 문헌 (Remington's Pharmaceutical Science, 최근, Mack Publishing Company, Easton PA)에 개시되어 있는 것을 이용하는 것이 바람직하다.The composition of the present invention may be administered in various oral or parenteral formulations during actual clinical administration. In the case of formulation, commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc. are used. and suitable formulations known in the art are preferably those disclosed in the literature (Remington's Pharmaceutical Science, recently Mack Publishing Company, Easton PA).
상기 경구 투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트(Calcium carbonate), 수크로스 (Sucrose) 또는 락토오스(Lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 또한, 상기 경구 투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. The solid preparation for oral administration includes tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient, for example, starch, calcium carbonate, sucrose, or It is prepared by mixing lactose and gelatin. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. In addition, the liquid formulations for oral administration include suspensions, internal solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients, for example, wetting agents, sweeteners, fragrances, preservatives, etc. this may be included.
상기 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like can be used.
본 발명의 약학적 조성물의 투여량은 상기 약학적 조성물의 제제화 방법, 투여 방식, 투여 시간 및/또는 투여 경로 등에 의해 다양해질 수 있으며, 상기 약학적 조성물의 투여로 달성하고자 하는 반응의 종류와 정도, 투여 대상이 되는 개체의 종류, 연령, 체중, 일반적인 건강 상태, 질병의 증세나 정도, 성별, 식이, 배설, 해당 개체에 동시 또는 이시에 함께 사용되는 약물 기타 조성물의 성분 등을 비롯한 여러 인자 및 의약 분야에서 잘 알려진 유사 인자에 따라 다양해질 수 있으며, 당해 기술 분야에서 통상의 지식을 가진 자는 목적하는 치료에 효과적인 투여량을 용이하게 결정하고 처방할 수 있다.The dosage of the pharmaceutical composition of the present invention may vary depending on the formulation method, administration method, administration time and/or route of administration of the pharmaceutical composition, and the type and extent of a response to be achieved by administration of the pharmaceutical composition. , various factors including the type of subject to be administered, age, weight, general health, symptoms or severity of disease, sex, diet, excretion, components of drugs or other compositions used simultaneously or at the same time in the subject; It may vary depending on similar factors well known in the medical field, and a person skilled in the art can easily determine and prescribe an effective dosage for a desired treatment.
본 발명의 약학적 조성물의 투여량은 예를 들어, 1 내지 500 mg/kg의 농도로 투여되는 것이 바람직하며, 더 바람직하게는 200 내지 450 mg/kg, 더욱 바람직하게는 300 내지 400 mg/kg, 더더욱 바람직하게는 360 mg/kg일 수 있으나, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The dosage of the pharmaceutical composition of the present invention, for example, is preferably administered at a concentration of 1 to 500 mg / kg, more preferably 200 to 450 mg / kg, more preferably 300 to 400 mg / kg , more preferably 360 mg/kg, but the dosage does not limit the scope of the present invention in any way.
본 발명의 약학적 조성물의 투여 경로 및 투여 방식은 각각 독립적일 수 있으며, 그 방식에 있어 특별히 제한되지 아니하며, 목적하는 해당 부위에 상기 약학적 조성물이 도달할 수 있는 한 임의의 투여 경로 및 투여 방식에 따를 수 있다. The administration route and administration method of the pharmaceutical composition of the present invention may be each independent, and the method is not particularly limited, and any administration route and administration method as long as the pharmaceutical composition can reach the desired site. can follow
상기 약학적 조성물은 경구 투여 또는 비경구 투여 방식으로 투여할 수 있다. 상기 비경구 투여 방식으로는 예를 들어 정맥 내 투여, 복강 내 투여, 근육 내 투여, 경피 투여 또는 피하 투여 등이 포함된다.The pharmaceutical composition may be administered by oral administration or parenteral administration. The parenteral administration method includes, for example, intravenous administration, intraperitoneal administration, intramuscular administration, transdermal administration, or subcutaneous administration.
본 발명의 약학적 조성물은 칼슘 결핍으로 인한 질환의 예방 또는 치료를 위하여 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers for the prevention or treatment of diseases caused by calcium deficiency.
본 발명의 또 다른 양태에 따르면, 본 발명은 누에고치 가수분해물 제조방법을 제공한다. 상기 제조방법은 (a) 누에고치의 세리신을 제거하는 단계; (b) 세리신이 제거된 누에고치를 산 처리하여 용해시키는 단계; 및 (c) 용해물을 중화 및 탈염하는 단계;를 포함하는 칼슘 흡수 촉진 및 관능이 개선된 식품 조성물 제조방법을 제공한다.According to another aspect of the present invention, there is provided a method for preparing a cocoon hydrolyzate. The manufacturing method comprises the steps of (a) removing the sericin of the cocoon; (b) dissolving the cocoon from which sericin has been removed by acid treatment; And (c) neutralizing and desalting the lysate; provides a method for preparing a food composition containing improved calcium absorption and sensory improvement.
본 발명의 구체예에서, 상기 단계 (a)는 누에고치를 올레산 나트륨 및 무수 탄산나트륨 용액과 반응시키는 것이 바람직하나, 이에 제한되지 않는다.In an embodiment of the present invention, in step (a), the cocoon is preferably reacted with sodium oleate and anhydrous sodium carbonate solution, but is not limited thereto.
본 발명의 구체예에서, 상기 단계 (b)의 산 처리는 1 내지 7시간 동안 처리하는 것이 바람직하며, 보다 바람직하게는 3 내지 6시간, 보다 더 바람직하게는 5시간일 수 있다. 산 처리 시간이 1시간 미만인 경우 가수분해가 이루어지지 않으며, 7시간 초과인 경우 과도한 산 처리로 인해 유효 성분이 감소한다는 문제가 있다. In an embodiment of the present invention, the acid treatment in step (b) is preferably performed for 1 to 7 hours, more preferably 3 to 6 hours, and even more preferably 5 hours. If the acid treatment time is less than 1 hour, hydrolysis does not occur, and if it exceeds 7 hours, there is a problem that the active ingredient decreases due to excessive acid treatment.
본 발명의 바람직한 구체예에서, 상기 단계 (b)의 산 처리는 누에고치 150 g당 염산 200 내지 600 ml과 물 400 내지 800 ml을 넣고 110 내지 130℃에서 용해시키는 것이 바람직하다. In a preferred embodiment of the present invention, in the acid treatment of step (b), 200 to 600 ml of hydrochloric acid and 400 to 800 ml of water per 150 g of cocoon are added and dissolved at 110 to 130°C.
본 발명의 구체예에서, 본 발명에 따른 칼슘 흡수 촉진 및 관능이 개선된 식품 조성물 제조방법은 탈염 단계, 건조 단계 또는 분쇄 단계를 더 포함할 수 있으나, 이에 제한되지 않는다.In an embodiment of the present invention, the method for preparing a food composition having improved calcium absorption and sensory according to the present invention may further include a desalting step, a drying step or a grinding step, but is not limited thereto.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples.
실시예 1. 세리신이 제거된 정련견 제조Example 1. Manufacture of refined dogs from which sericin has been removed
누에고치에 포함된 세리신을 제거하여, 정련견을 제조하였다. 구체적으로, 정련견 제조는 세리신 제거 단계;와 세척 및 건조 단계;를 거쳐 제조하였다.By removing the sericin contained in the cocoon, a refined dog was prepared. Specifically, the scouring dog was manufactured through a sericin removal step; and a washing and drying step.
1-1. 세리신 제거 단계 : 끓는 물 8 L에 절각한 누에고치 150 g, 올레산나트륨(Sodium oleate) 0.75 g 및 무수 탄산나트륨(Soldium Carbonate, Anhydrous) 0.45 g을 넣고 40분 동안 가열하였다. 가열 중 누에고치를 10분 마다 저어주었다. 가열 종료 후 누에고치를 탈수하였다. 본 과정을 2 내지 3회 반복하였다. 1-1. Sericin removal step: 150 g of cut cocoon, 0.75 g of sodium oleate and 0.45 g of anhydrous sodium carbonate (Soldium Carbonate, Anhydrous) were put in 8 L of boiling water and heated for 40 minutes. The cocoon was stirred every 10 minutes during heating. After completion of heating, the cocoon was dehydrated. This process was repeated 2-3 times.
1-2. 세척 및 건조 단계 : 세리신 제거 단계를 거친 누에고치를 끓는 물 8 L에서 20분 동안 끓인 후 탈수하였으며, 상기 세척 과정을 3회 반복하였다. 세척된 누에고치를 건조기에서 5시간 이상 건조하여, 정련견을 제조하였다. 1-2. Washing and drying step: After boiling the cocoon that had undergone the sericin removal step in 8 L of boiling water for 20 minutes, it was dehydrated, and the washing process was repeated 3 times. The washed cocoon was dried in a dryer for more than 5 hours to prepare a refined dog.
실시예 2. 누에고치 가수분해물 제조Example 2. Cocoon hydrolyzate preparation
정련견을 이용한 누에고치 가수분해물 제조방법을 도 1에 간략히 나타내었다. 구체적으로, 누에고치 통고치 또는 상기 실시예 1에서 제조된 정련견 150 g을 전체부피 1000 ml 용액(염산 300 ml + 증류수 700 ml)에 담궈 121 ℃에서 5시간 동안 가수분해시켰다. 상기 가수분해물을 다시 3M NaOH로 적정하여 pH가 6.5~7.0이 되도록 중화시켰다. 그 후, 부직포로 2회, 필터페이퍼(No.2) 2회, 0.8 μm 필터로 여과한 후 전기투석장치(전압 15V, 전류 1~3mV)를 이용하여 탈염하였다. 상기 탈염물을 동결건조하여, 누에고치 가수분해물을 완성하였다.A method for preparing a hydrolyzate of a silkworm cocoon using a scouring dog is briefly shown in FIG. 1 . Specifically, 150 g of silkworm cocoon or refined silk prepared in Example 1 was immersed in a total volume of 1000 ml solution (hydrochloric acid 300 ml + distilled water 700 ml) and hydrolyzed at 121° C. for 5 hours. The hydrolyzate was again titrated with 3M NaOH to neutralize the pH to 6.5-7.0. After that, it was filtered with a nonwoven fabric twice, filter paper (No. 2) twice, and a 0.8 μm filter, and then desalted using an electrodialysis device (voltage 15V, current 1-3mV). The desalted product was freeze-dried to complete a cocoon hydrolyzate.
실시예 3. 누에고치 가수분해물의 칼슘 흡수 촉진 효과 확인Example 3. Confirmation of calcium absorption promoting effect of cocoon hydrolyzate
8주령 수컷 Sprague-Dawley 종을 각 실험군 당 10 마리씩 준비하였다. 준비된 실험동물에 누에고치 가수분해물 360 mg/kg 및 칼슘원인 중질탄산칼슘을 100 mg/kg의 농도로 4주 동안 투여하였다. 투여 종료 후 실험동물의 혈액을 채취하여 칼슘 농도를 측정하였다. 상기 칼슘 농도 측정은 실험동물의 혈액을 3,000 rpm에서 10분 동안 원심분리한 후 제조사의 매뉴얼에 따라 OCPC(ο-cresolphthalein complexone) 방법으로 측정하였다.Eight-week-old male Sprague-Dawley strains were prepared by 10 animals in each experimental group. 360 mg/kg of cocoon hydrolyzate and ground calcium carbonate, a calcium source, were administered to the prepared experimental animals at a concentration of 100 mg/kg for 4 weeks. After the end of administration, blood was collected from the experimental animals and the calcium concentration was measured. The calcium concentration was measured by OCPC (ο-cresolphthalein complexone) method according to the manufacturer's manual after centrifuging the blood of an experimental animal at 3,000 rpm for 10 minutes.
본 실시예에서, 음성 대조군은 중질탄산칼슘만을 투여하였으며, 양성 대조군은 중질탄산칼슘 및 칼슘흡수에 도움을 주는 건강기능식품(In-Calcium Absorb)을 360 mg/kg의 농도로 투여하였다.In this example, the negative control group was administered only ground calcium carbonate, the positive control group was administered with heavy calcium carbonate and a health functional food (In-Calcium Absorb) to help calcium absorption at a concentration of 360 mg / kg.
실험동물의 혈청 내에 포함된 칼슘의 농도를 분석한 결과는 도 2에 나타내었다.The results of analyzing the concentration of calcium contained in the serum of the experimental animals are shown in FIG. 2 .
도 2에 나타낸 바와 같이, 누에고치 가수분해물 투여군은 음성 대조군보다 혈청 내 칼슘 함량이 높은 것을 확인하였다. 또한 누에고치 가수분해물 투여군은 칼슘 흡수에 도움을 주는 건강기능식품(In-Calcium Absorb)을 함께 투여한 양성 대조군보다 혈청 내 칼슘 함량이 높은 것을 알 수 있다. 상기 결과는 누에고치 가수분해물이 생체 내에서 칼슘 흡수 촉진 효과가 우수하다는 나타낸다.As shown in FIG. 2 , it was confirmed that the cocoon hydrolyzate administration group had a higher serum calcium content than the negative control group. In addition, it can be seen that the cocoon hydrolyzate administration group had a higher serum calcium content than the positive control group administered together with a health functional food (In-Calcium Absorb) that helps calcium absorption. The above results indicate that the cocoon hydrolyzate is excellent in promoting calcium absorption in vivo.
실시예 4. 누에고치 가수분해물의 성분 분석Example 4. Component Analysis of Cocoon Hydrolyzate
상기 실시예 2의 누에고치 가수분해물을 100 ml 씩 원심분리용 튜브에 넣은 후, 4 ℃를 유지한 후 15,000 rpm에서 30분 동안 원심분리하였다. 원심분리 후 침전물을 분리하여 상등액만을 얻었다. 상기 상등액을 건조한 후 구연산(pH 2.2)으로 희석하고, 자동 아미노산 분석장치로 유리 아미노산의 함량을 조사하였다. 100 ml of the cocoon hydrolyzate of Example 2 was placed in a centrifuge tube, and then centrifuged at 15,000 rpm for 30 minutes after maintaining 4°C. After centrifugation, the precipitate was separated to obtain only the supernatant. After drying the supernatant, it was diluted with citric acid (pH 2.2), and the content of free amino acids was investigated with an automatic amino acid analyzer.
이때, 대조군 1로는 누에고치와 증류수의 비율을 1:30으로 하여 115 ℃에서 5시간 동안 반응을 시켜 얻은 용액을 동결건조하여 얻은 세리신을 사용하였다. In this case, as Control 1, sericin obtained by freeze-drying a solution obtained by reacting at 115° C. for 5 hours at a ratio of cocoon and distilled water of 1:30 was used.
또한, 대조군 2로는 다음과 같이 제조된 피브로인을 사용하였다. 상기 피브로인 제조하기 위하여, 누에고치 150 g을 올레산 나트륨 0.75 g, 탄산나트륨 0.45 g과 증류수 8 L를 40분 동안 100 ℃에서 끓이는 작업을 2회 실시하였다. 이후 100 ℃의 증류수에서 끓이는 작업을 2회 실시하여 건조시켜 세리신이 제거된 순수한 피브로인을 얻었다. 상기 피브로인 35 g을 물 : 알콜 : 염화칼슘 = 8 : 2 : 1(몰비율)의 용액 1 L에 넣은 후 85 ℃이상의 히팅맨틀에서 7 시간 동안 용해시키고, 투석막에 용해된 피브로인 용액을 넣어 3일 동안 투석하여 염을 제거하였다. 염이 제거된 피브로인 용액을 동결건조하여 피브로인을 제조하였다.In addition, as Control 2, fibroin prepared as follows was used. In order to prepare the fibroin, the operation of boiling 150 g of cocoon with 0.75 g of sodium oleate, 0.45 g of sodium carbonate and 8 L of distilled water at 100° C. for 40 minutes was performed twice. After that, boiling was performed twice in distilled water at 100 ° C. and dried to obtain pure fibroin from which sericin was removed. After putting 35 g of the fibroin in 1 L of a solution of water: alcohol: calcium chloride = 8: 2: 1 (molar ratio), it was dissolved in a heating mantle at 85 ° C. or higher for 7 hours, and the fibroin solution dissolved in the dialysis membrane was added for 3 days. The salt was removed by dialysis. The salt-removed fibroin solution was freeze-dried to prepare fibroin.
상기 실시예 2에서 제조된 누에고치 가수분해물, 대조군 1(세리신) 및 대조군 2(피브로인)의 유리아미노산의 함량을 분석한 결과는 표 1에 나타내었다. The results of analyzing the free amino acid content of the cocoon hydrolyzate prepared in Example 2, Control 1 (sericin) and Control 2 (fibroin) are shown in Table 1.
(세리신)Control 1
(sericin)
(피브로인)Control 2
(fibroin)
(THR)threonine
(THR)
(SER)serine
(SER)
(GLU)glutamic acid
(GLU)
(GLY)glycine
(GLY)
(ALA)alanine
(ALA)
(VAL)valine
(VAL)
(IIe)isoleucine
(IIe)
(Leu)leucine
(Leu)
(Tyr)Tyrosine
(Tyr)
(Phe)phenylalanine
(Phe)
(Lys)lysine
(Lys)
(His)histidine
(His)
(Arg)arginine
(Arg)
(Pro)proline
(Pro)
표 1에 나타낸 바와 같이, 상기 실시예 2에서 제조된 누에고치 가수분해물은 대조군 1인 세리신보다 글리신(GLY), 알라닌(ALA), 타이로신(Tyr), 페닐알라닌(Phe)이 상대적으로 높게 나타났으며, 대조군 2인 피브로인보다는 아스파르트산(ASP), 트레오닌(THR), 세린(SER), 글루탐산(GLU), 발린(VAL), 이소루신(IIe), 루신(Leu), 페닐알라닌(Phe), 프롤린(Pro)가 상대적으로 높게 나타났다. 상기 결과는 누에고치 자체가 갖고 있는 성분, 즉, 유리 아미노산의 함량을 보다 상승시키기 위해서는 상기 실시예 2와 같이 특정 가수분해과정을 거쳐야 함을 알 수 있다.As shown in Table 1, in the cocoon hydrolyzate prepared in Example 2, glycine (GLY), alanine (ALA), tyrosine (Tyr), and phenylalanine (Phe) were relatively higher than that of control 1, sericin. , aspartic acid (ASP), threonine (THR), serine (SER), glutamic acid (GLU), valine (VAL), isoleucine (IIe), leucine (Leu), phenylalanine (Phe), proline ( Pro) was relatively high. The above results show that in order to further increase the content of the component of the cocoon itself, that is, free amino acids, a specific hydrolysis process as in Example 2 is required.
실시예 5. 누에고치 가수분해물의 기호도 조사Example 5. Investigation of the preference of cocoon hydrolyzate
5-1. 누에고치 가수분해물의 당도 및 감칠맛 분석5-1. Analysis of sugar content and umami of cocoon hydrolyzate
상기 실시예 2에서 제조된 누에고치 가수분해물의 당도 및 감칠맛을 분석하였다. 구체적으로, 본 실시예의 실험군 1은 상기 실시예 2에서 제조된 누에고치 가수분해물이며, 실험군 2는 상기 실시예 2와 동일하게 제조하되 3시간 동안 가수분해시킨 것이다. 시료(실험군 1, 실험군 2 또는 대조군) 0.1 g씩을 증류수 1 ml에 용해시켜 당도 및 감칠맛을 분석하였으며, 그 결과는 표 2에 나타내었다.The sugar content and umami taste of the cocoon hydrolyzate prepared in Example 2 were analyzed. Specifically, Experimental Group 1 of this example is the cocoon hydrolyzate prepared in Example 2, and Experimental Group 2 is prepared in the same manner as in Example 2, but hydrolyzed for 3 hours. 0.1 g of each sample (experimental group 1, experimental group 2, or control group) was dissolved in 1 ml of distilled water to analyze the sugar content and umami taste, and the results are shown in Table 2.
(정련견 이용)Experimental group 1
(Using refined dogs)
(정련견 이용)Experimental group 2
(Using refined dogs)
(세리신 함유 시)control
(with sericin)
표 2에 나타낸 바와 같이, 실험군 1 및 2는 대조군보다 당도 및 감칠맛이 높은 것을 확인하였다. 특히, 실험군 1 및 2의 당도는 설탕의 당도(8.8 brix, 0.1 g/ml)보다 높은 수치임을 알 수 있다.As shown in Table 2, it was confirmed that experimental groups 1 and 2 had higher sugar content and umami than the control group. In particular, it can be seen that the sugar content of experimental groups 1 and 2 is higher than that of sugar (8.8 brix, 0.1 g/ml).
5-2. 누에고치 가수분해물의 관능검사5-2. Sensory test of cocoon hydrolyzate
상기 실시예 5-1의 실험군 1 및 2의 관능검사(맛)를 시행하였다. 이 때, 관능검사는 연령과 성별을 고려하여 10 대 ~ 40 대 성인 남녀를 각각 연령대별로 10 명씩 총 40 명을 선발한 후, 이들을 대상으로 5점 척도법(0점 : 매우 나쁨, 1점 : 나쁨, 2점 : 보통임, 3점 : 괜찮음, 4점 : 좋음, 5점 : 매우 좋음)을 이용하여 평가하였다. 관능검사 결과는 표 3에 나타내었다.The sensory test (taste) of Experimental Groups 1 and 2 of Example 5-1 was performed. At this time, for the sensory test, a total of 40 men and women in their teens and 40s were selected in consideration of age and gender, 10 for each age group, and then a 5-point scale method (0 points: very bad, 1 point: poor) , 2 points: average, 3 points: good, 4 points: good, 5 points: very good). The sensory test results are shown in Table 3.
기호도comprehensive
symbol
표 3에 나타낸 바와 같이, 세리신 제거 및 가수분해로 인해 실험군 1 및 2는 쓴맛 및 신맛이 감소하고, 단맛이 증가한 것을 확인하였다. 반면에, 대조군은 쓴맛이 높게 평가되었다. 종합적인 기호도는 실험군 1 및 2가 대조군보다 약 3.7배 높았다.As shown in Table 3, it was confirmed that the bitterness and sourness of the experimental groups 1 and 2 decreased and the sweetness increased due to the removal and hydrolysis of sericin. On the other hand, the control group was highly rated for bitterness. The overall acceptability was about 3.7 times higher in experimental groups 1 and 2 than in the control group.
종합적으로 본 발명자들은 누에고치 가수분해물을 제조하고, 이의 유리 아미노산 함량 증가 및 체내 칼슘 흡수 촉진 효과를 확인하였다. 뿐만 아니라 상기 누에고치 가수분해물은 단맛이 증가하여 종합적인 기호도가 현저히 높은 것을 확인하였다. 따라서 본 발명의 누에고치 가수분해물은 첨가제, 건강기능식품, 사료 등을 포함하는 식품 분야에서 다양하게 활용될 수 있다.Overall, the present inventors prepared a cocoon hydrolyzate, and confirmed the effect of increasing the free amino acid content and promoting calcium absorption in the body. In addition, it was confirmed that the hydrolyzate of the cocoon had a significantly higher overall taste due to increased sweetness. Therefore, the cocoon hydrolyzate of the present invention can be variously used in the food field including additives, health functional foods, feeds, and the like.
이하, 제제예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 제제예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 제제예에 의해 제한되는 것으로 해석되지 않는다.Hereinafter, the present invention will be described in more detail through formulation examples. The formulation examples are only for illustrating the present invention, and the scope of the present invention is not to be construed as being limited by the formulation examples.
제제예 1. 식품 조성물의 제조Formulation Example 1. Preparation of food composition
1-1.건강기능식품의 제조1-1. Manufacture of health functional food
누에고치 가수분해물 100 mg100 mg of cocoon hydrolyzate
비타민 혼합물 적량appropriate amount of vitamin mixture
비타민 A 아세테이트 70 g 70 g vitamin A acetate
비타민 E 1.0 mgVitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mgVitamin B2 0.15 mg
비타민 B6 0.5 mg0.5 mg of vitamin B6
비타민 B12 0.2 g 0.2 g of vitamin B12
비타민 C 10 mgVitamin C 10 mg
비오틴 10 g 10 g of biotin
니코틴산아미드 1.7 mg1.7 mg of nicotinic acid amide
엽산 50 g 50 g folic acid
판토텐산 칼슘 0.5 mgCalcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture appropriate amount
황산제1철 1.75 mgferrous sulfate 1.75 mg
산화아연 0.82 mgZinc Oxide 0.82 mg
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgpotassium phosphate monobasic 15 mg
제2인산칼슘 55 mgDicalcium Phosphate 55 mg
구연산칼륨 90 mgPotassium citrate 90 mg
탄산칼슘 100 mg100 mg of calcium carbonate
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.The composition ratio of the vitamin and mineral mixture is a composition that is relatively suitable for health food in a preferred embodiment, but the mixing ratio may be arbitrarily modified, and the ingredients are mixed according to a conventional health food manufacturing method. , to prepare granules, and can be used for preparing health food compositions according to a conventional method.
1-2. 건강음료의 제조1-2. Manufacturing of health drinks
누에고치 가수분해물 100 mg100 mg of cocoon hydrolyzate
비타민 C 15 g15 g vitamin C
비타민 E(분말) 100 g100 g vitamin E (powder)
젖산철 19.75 g19.75 g of iron lactate
산화아연 3.5 g3.5 g zinc oxide
니코틴산아미드 3.5 g3.5 g of nicotinic acid amide
비타민 A 0.2 g0.2 g vitamin A
비타민 B1 0.25 g0.25 g of vitamin B1
비타민 B2 0.3 g0.3 g of vitamin B2
물 정량water metering
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 ℃ 에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. 상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.After mixing the above ingredients according to the usual health drink manufacturing method, after stirring and heating at 85 ° C for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, then refrigerated. It is used to prepare the health drink composition of the invention. Although the composition ratio is prepared by mixing ingredients suitable for comparatively favorite beverages in a preferred embodiment, the mixing ratio may be arbitrarily modified according to regional and national preferences such as the demanding class, the demanding country, and the use.
제제예 2. 약학적 조성물의 제조Formulation Example 2. Preparation of pharmaceutical composition
2-1. 산제의 제조2-1. Preparation of powders
누에고치 가수분해물 20 mgCocoon hydrolyzate 20 mg
유당 100 mgLactose 100 mg
탈크 10 mgtalc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight bag to prepare a powder.
2-2. 정제의 제조2-2. manufacture of tablets
누에고치 가수분해물 10 mgCocoon hydrolyzate 10 mg
옥수수전분 100 mg100 mg cornstarch
유당 100 mgLactose 100 mg
스테아린산 마그네슘 2 mg2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above ingredients, tablets are prepared by tableting according to a conventional manufacturing method of tablets.
제제예 3. 사료 첨가제의 제조Formulation Example 3. Preparation of feed additives
누에고치 가수분해물 2.0%Cocoon Hydrolyzate 2.0%
글루코스 2.0 %glucose 2.0%
펩톤 1.0 %Peptone 1.0%
효모추출물 1.0 %Yeast Extract 1.0%
제이인산 0.2 %Diphosphate 0.2%
황산마그네슘 0.05 %Magnesium sulfate 0.05 %
시스테인 0.05 % Cysteine 0.05%
정제수 to 100 %Purified water to 100 %
부형제 탈지강 적량Excipient defatted steel appropriate amount
이상, 본 발명내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적인 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의해 정의된다고 할 것이다. Above, a specific part of the present invention has been described in detail, for those of ordinary skill in the art, it is clear that this specific description is only a preferred embodiment, and the scope of the present invention is not limited thereby. something to do. Accordingly, it is intended that the substantial scope of the present invention be defined by the appended claims and their equivalents.
Claims (14)
상기 누에고치는 정련견인, 식품 조성물.According to claim 1,
The cocoon is a refining traction, a food composition.
상기 누에고치 가수분해물은 아스파르트산, 이소루신, 타이로신, 페닐알라닌 및 프롤린으로 이루어진 군에서 선택된 1 이상의 아미노산 함량이 증진된 것인, 식품 조성물.According to claim 1,
The cocoon hydrolyzate is that the content of one or more amino acids selected from the group consisting of aspartic acid, isoleucine, tyrosine, phenylalanine and proline is enhanced, the food composition.
상기 누에고치 가수분해물은 당도가 증진된 것인, 식품 조성물.According to claim 1,
The cocoon hydrolyzate is that the sugar content is enhanced, the food composition.
상기 당도는 5 내지 16 brix인, 식품 조성물.5. The method of claim 4,
The sugar content is 5 to 16 brix, the food composition.
상기 누에고치 가수분해물은 쓴맛 및 신맛이 감소된 것인, 식품 조성물.According to claim 1,
The cocoon hydrolyzate is a food composition that has reduced bitterness and sour taste.
상기 칼슘 결핍으로 인한 질환은 구루병, 골다공증, 골연화증, 테타니, 부종, 고콜레스테롤증, 동맥경화, 고지혈증 및 고혈압으로 이루어진 군에서 선택된 1 이상인, 약학적 조성물.10. The method of claim 9,
The disease caused by calcium deficiency is at least one selected from the group consisting of rickets, osteoporosis, osteomalacia, tetanus, edema, hypercholesterolemia, arteriosclerosis, hyperlipidemia and hypertension, a pharmaceutical composition.
(b) 세리신이 제거된 누에고치를 산 처리하여 용해시키는 단계; 및
(c) 용해물을 중화 및 탈염하는 단계;를 포함하는 칼슘 흡수 촉진 및 관능이 개선된 식품 조성물의 제조방법.(a) removing the sericin of the cocoon;
(b) dissolving the cocoon from which sericin has been removed by acid treatment; and
(c) neutralizing and desalting the lysate; facilitating calcium absorption and a method of producing a food composition comprising improved sensory.
상기 단계 (a)는 누에고치를 올레산 나트륨 및 무수 탄산나트륨 용액과 반응시키는 것인, 제조방법.12. The method of claim 11,
The step (a) is to react the cocoon with sodium oleate and anhydrous sodium carbonate solution.
상기 단계 (b)의 산 처리는 1 내지 7시간 동안 처리하는 것인, 제조방법.12. The method of claim 11,
The acid treatment of step (b) will be treated for 1 to 7 hours, the manufacturing method.
상기 단계 (b)의 산 처리는 누에고치 150 g당 염산 200 내지 600 ml과 물 400 내지 800 ml을 넣고 110 내지 130℃에서 용해시키는 것인, 제조방법.12. The method of claim 11,
In the acid treatment of step (b), 200 to 600 ml of hydrochloric acid and 400 to 800 ml of water per 150 g of cocoon are added and dissolved at 110 to 130°C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190166223A KR20210076222A (en) | 2019-12-13 | 2019-12-13 | Calcium absorption promoting composition comprising cocoon hydrolysate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190166223A KR20210076222A (en) | 2019-12-13 | 2019-12-13 | Calcium absorption promoting composition comprising cocoon hydrolysate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210076222A true KR20210076222A (en) | 2021-06-24 |
Family
ID=76607378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190166223A KR20210076222A (en) | 2019-12-13 | 2019-12-13 | Calcium absorption promoting composition comprising cocoon hydrolysate |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20210076222A (en) |
-
2019
- 2019-12-13 KR KR1020190166223A patent/KR20210076222A/en not_active IP Right Cessation
Non-Patent Citations (2)
| Title |
|---|
| Lee, J.-Y., Park, Y.-S., Kim, Y.-H., Oh, K.-H., Hwang, K.-Y., Cho, Y.-S., … Seong, S.-I. (2008). Effect of New Calcium Supplementary Food Containing Fermented Product of Bacillus on the Longitudinal Bone Growth in the Adolescent Male Rats. Journal of the Korean Society of Food Science and Nutrition, 37(12), 1576-1582. |
| 이진경, Lim, Yeong-Seon, 주동식, & Jeong, In-Hak. (2002). 동해산 재래종 다시마 (Kjellemaniella crassifolia)의 식이가 흰쥐 체내의 칼슘흡수, 혈액조성 및 분변에 미치는 영향. 한국수산과학회지, 35(6), 601-607. |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101982326B1 (en) | Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions | |
| US20100105867A1 (en) | Process for producing osteocalcin-containing extract | |
| CN102395376A (en) | Lipid metabolism-improving agent | |
| KR20140020951A (en) | Skin-beautifying agent | |
| JP2010018522A (en) | Adiponectin production enhancer | |
| JP5208428B2 (en) | Skin care | |
| JP3691685B2 (en) | Blood sugar level rise inhibitor | |
| KR20080006789A (en) | Cooperation material of feed using a pig breeding containted a by-product of korea raspbrry and that of method of manufacture | |
| WO2017119476A1 (en) | Composition for preventing neurological diseases | |
| CN105795149A (en) | Piglet milk powder with high nutrition and high absorbability and preparation method thereof | |
| WO2012014783A1 (en) | Acidic soluble soybean protein material and production method thereof | |
| KR20210076222A (en) | Calcium absorption promoting composition comprising cocoon hydrolysate | |
| KR20190017704A (en) | Composition for stimulation of bone formation comprising Curcuma xanthorrhiza extract or xanthorrhizol as effective component | |
| JP5712393B2 (en) | Collagen absorption promoter and use thereof | |
| WO2016133155A1 (en) | α-GLUCOSIDASE INHIBITOR | |
| KR101799781B1 (en) | Method for Manufacturing Extract Powder of Cattle Bone | |
| JP6083085B2 (en) | Angiotensin converting enzyme inhibitor and use thereof | |
| CN102573880B (en) | Fat accumulation suppressor | |
| KR101322282B1 (en) | Composition for bone growth promotion comprising Gelatin hydrolysates | |
| KR100899556B1 (en) | Functional Foods Adding Sargassum spp. Extracts | |
| JP2005097162A (en) | Anti-fatigue composition containing glutamine peptide | |
| EP3749339A1 (en) | Marine protein hydrolysate with low fluoride and trimethylamin content | |
| KR102253996B1 (en) | Anti-hypertensive composition comprising peptides derived from hydrolysates of Paralichthys olivaceus | |
| JP2003277273A (en) | Mineral absorption-promoting agent | |
| KR20050003989A (en) | Egg derivatives having bone-strengthening effects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X601 | Decision of rejection after re-examination |